Ibrutinib

Combination ibrutinib and venetoclax for first-line treatment yielded a 5-year PFS of 90.1% and 5-year OS of 95.6% in 120 patients with chronic lymphocytic leukemia, according to long-term follow-up data presented at ASH Annual Meeting.

Ibrutinib plus venetoclax demonstrated superior PFS and a higher complete response rate compared with ibrutinib plus placebo in patients with relapsed or refractory mantle cell lymphoma, according to study results.

SAN DIEGO — Individuals treated with first-generation Bruton tyrosine kinase inhibitors with preexisting cardiovascular disease had significantly higher odds of developing cardiovascular adverse events, study results showed.

SAN DIEGO — A combination of targeted therapies used for a response-directed duration significantly improved outcomes compared with chemoimmunotherapy for fit patients with untreated chronic lymphocytic leukemia, according to study results.

Healio spoke with Ryan. W. Jacobs, MD, about challenges in the treatment of CLL.

Healio spoke with Ryan. W. Jacobs, MD, about treatment options available to patients with CLL.

Healio spoke with Ryan. W. Jacobs, MD, about recent advancements in the management of CLL.

This year’s ASCO Annual Meeting included essential research updates across the field.

A phase 2 trial of axatilimab for chronic graft-versus-host disease met its primary endpoint, according to the agent’s manufacturer.

In this video, Jakub Svoboda, MD, discusses the results of the phase 3 Alliance study, pertaining to chronic lymphocytic leukemia, presented at ASCO Annual Meeting.